| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDKN2D |
| Uniprot No | P55273 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-166aa |
| 氨基酸序列 | MLLEEVRAGDRLSGAAARGDVQEVRRLLHRELVHPDALNRFGKTALQVMMFGSTAIALELLKQGASPNVQDTSGTSPVHDAARTGFLDTLKVLVEHGADVNVPDGTGALPIHLAVQEGHTAVVSFLAAESDLHRRDARGLTPLELALQRGAQDLVDILQGHMVAPL |
| 预测分子量 | 44.7kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDKN2D重组蛋白的3篇参考文献示例(注：文献为虚构，仅作格式参考)：
---
1. **标题**: *Functional characterization of recombinant CDKN2D in cell cycle regulation*
**作者**: Smith A, et al.
**摘要**: 研究通过大肠杆菌表达重组CDKN2D蛋白，验证其与CDK4/6的特异性结合能力，并证明其在体外抑制激酶活性，诱导细胞周期G1期阻滞。
2. **标题**: *Structural insights into CDKN2D-CDK6 interaction using recombinant protein*
**作者**: Johnson B, et al.
**摘要**: 利用重组CDKN2D蛋白进行X射线晶体学分析，揭示了其与CDK6结合的分子机制，为设计靶向细胞周期调控的药物提供结构基础。
3. **标题**: *Recombinant CDKN2D enhances chemosensitivity in glioblastoma models*
**作者**: Lee C, et al.
**摘要**: 在胶质母细胞瘤细胞中递送重组CDKN2D蛋白，发现其通过恢复细胞周期检查点功能，显著增强肿瘤细胞对替莫唑胺的敏感性。
---
**注**：以上文献为示例，实际研究中建议通过PubMed或Web of Science检索真实文献(关键词：CDKN2D/p19INK4d + recombinant/expression)。
CDKN2D (Cyclin-Dependent Kinase Inhibitor 2D), also known as p18INK4C, is a member of the INK4 family of cell cycle regulators. This protein is encoded by the CDKN2D gene located on human chromosome 19p13.2. It functions as a tumor suppressor by inhibiting cyclin-dependent kinases CDK4 and CDK6. which are critical for G1-to-S phase progression in the cell cycle. By binding to these kinases, p18INK4C prevents phosphorylation of the retinoblastoma (RB) protein, thereby maintaining RB in its active, growth-suppressive state and blocking cell cycle progression. Its expression is tightly regulated during cellular differentiation, senescence, and stress responses.
Recombinant CDKN2D protein is produced through genetic engineering techniques, often using bacterial or mammalian expression systems. This purified protein serves as a tool for studying cell cycle mechanisms, cancer biology, and therapeutic development. Researchers utilize it to explore p18INK4C's role in tumor suppression, its interactions with CDKs, and its potential as a biomarker or therapeutic target in cancers where CDKN2D is dysregulated. Interestingly, CDKN2D exhibits context-dependent functions, as some studies suggest paradoxical overexpression in certain malignancies, highlighting the complexity of its regulatory network.
Studies involving recombinant CDKN2D have also clarified its involvement in non-cancerous processes, such as neuronal differentiation and immune regulation. Challenges remain in fully elucidating its dual roles in tumor suppression and disease progression, as well as optimizing delivery strategies for potential therapeutic applications. Recombinant protein-based assays continue to advance understanding of CDKN2D's structural motifs and post-translational modifications that influence its stability and activity.
×
